The anatomy and physiology of human airways, bronchodilator drugs and their delivery
systems and pharmacokinetics, and bronchial asthma and methacholine or histamine …

Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal
experiments to produce a more prolonged bronchodilator effect than currently available beta …

The long-acting β2-agonist salmeterol has been shown in several in vitro studies to produce
non-β-mediated relaxant effects. The aim of the present study was to investigate whether …

According to the duration of bronchodilation, beta-2-agonists are divided into short and long
acting bronchodilators. The bronchodilatory effect of available long acting beta-2-agonists …

To study whether it would be possible to assess bronchodilating drugs in healthy subjects
with methacholine—induced bronchoconstriction, salbutamol 100, 200 and 300 μg was …

We compared the speed of action of the long acting β-agonist salmeterol with that of
salbutamol in order to assess whether reported in vitro differences are likely to have clinical …

Salmeterol is an inhaled long-acting selective β2-adrenoceptor agonist that is commercially
available as the xinafoate (1-hydroxy-2-naphthoic acid) salt of the racemic mixture of the two …

Salmeterol and formoterol display similar β 2 selectivity to salbutamol, but both are more
potent than the latter. In vitro studies suggest that salmeterol is a partial β 2 agonist. This …

In the November 1995 issue (CHEST 1995; 108: 1235–39), Bhagat and colleagues
presented a well-designed placebo-controlled, double-blind, crossover study suggesting …

Chronic obstructive pulmonary disease (COPD) is a condition in which continuous
bronchodilation may have clinical advantages. This study evaluated salmeterol, a β-agonist …